Raywatt Inc. has raised $9.7M in Series B funding to push its intravascular imaging technology further into cardiovascular care. The company's optical coherence tomography platform captures high-resolution 2D and 3D images of blood vessels at 400 frames per second.
Raywatt says its approach cuts down on contrast agent use, reducing side effects for patients, and pairs the imaging with an AI-driven FFR simulator meant to support treatment decisions. Founded in 2019 by a team with backgrounds in medicine, engineering, and optics, the company is targeting cardiovascular disease, the world's leading cause of death.












